Bone Marrow TransplantationBone MarrowTransplantation, HomologousBone Marrow CellsGraft vs Host DiseaseTransplantation, AutologousTissue DonorsKidney TransplantationLiver TransplantationWhole-Body IrradiationGraft SurvivalHematopoietic Stem Cell TransplantationAnemia, AplasticLeukemiaTransplantation ConditioningHistocompatibility TestingTissue and Organ ProcurementBone and BonesTransplantation ChimeraGraft RejectionLiving DonorsImmunosuppressive AgentsOrgan TransplantationBone Marrow PurgingTreatment OutcomeBusulfanHematopoietic Stem CellsHistocompatibilityTime FactorsRetrospective StudiesBone Marrow DiseasesRecurrenceTransplantation, IsogeneicCyclophosphamideHeart TransplantationTransplantationHematopoiesisLung TransplantationHematologic NeoplasmsWaiting ListsLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositiveBone Marrow ExaminationCytomegalovirus InfectionsMice, Inbred C57BLCombined Modality TherapyRadiation ChimeraSurvival AnalysisImmunosuppressionPrecursor Cell Lymphoblastic Leukemia-LymphomaTransplantsBone Marrow NeoplasmsHepatic Veno-Occlusive DiseaseLiver FailureRemission InductionGraft vs Host ReactionAcute DiseaseCyclosporineSurvival RateTransplantation ImmunologyLymphocyte DepletionLeukemia, MyeloidFollow-Up StudiesLymphoma, Non-HodgkinHLA AntigensDonor SelectionColony-Forming Units AssayLeukocyte TransfusionStem Cell TransplantationT-LymphocytesMyelodysplastic SyndromesPostoperative ComplicationsHematologic DiseasesChimeraSevere Combined ImmunodeficiencyBone RemodelingPancreas TransplantationNuclear FamilyHospitals, SpecialLymphocyte TransfusionActuarial AnalysisCadaverOpportunistic InfectionsCell DifferentiationImmunocompromised HostLeukocyte CountAntineoplastic Combined Chemotherapy ProtocolsPancytopeniaFatal OutcomePrognosisDirected Tissue DonationDisease-Free SurvivalSpleenAntilymphocyte SerumProspective StudiesRisk FactorsGraft vs Tumor EffectMice, Inbred BALB CFlow CytometryGranulocyte Colony-Stimulating Factor